R. Gervais

2.2k total citations
75 papers, 1.3k citations indexed

About

R. Gervais is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R. Gervais has authored 75 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in R. Gervais's work include Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (26 papers) and Lung Cancer Diagnosis and Treatment (19 papers). R. Gervais is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (26 papers) and Lung Cancer Diagnosis and Treatment (19 papers). R. Gervais collaborates with scholars based in France, Luxembourg and United Kingdom. R. Gervais's co-authors include Fabrice Barlési, G. Robinet, H. Léna, C. Chouaïd, I. Monnet, D. Paillotin, Abdesslam Chajara, J. Hureaux, S. Bota and H. Bérard and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

R. Gervais

70 papers receiving 1.2k citations

Peers

Countries citing papers authored by R. Gervais

Since Specialization

Citations

This map shows the geographic impact of R. Gervais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Gervais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Gervais more than expected).

Fields of papers citing papers by R. Gervais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Gervais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Gervais. The network helps show where R. Gervais may publish in the future.

Co-authorship network of co-authors of R. Gervais

This figure shows the co-authorship network connecting the top 25 collaborators of R. Gervais. A scholar is included among the top collaborators of R. Gervais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Gervais. R. Gervais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Women’s caring responsibilities as they age: assessing the Sandwich Generation’s satisfaction with life and well-being 2024 ·Community Work & Family ·R. Gervais, Prudence Millear	0
2	LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer 2020 ·Annals of Oncology ·Benjamin Besse, Jessica Menis, Paolo Bironzo, R. Gervais, Laurent Greillier, I. Monnet, Lorenzo Livi, Robyn R. Young, C. Decroisette, Nicolas Cloarec, G. Robinet, Roland Schött, Raffaele Califano, Filippo de Marinis, Giuseppe Luigi Banna, Murielle Mauer, (unknown), Baktiar Hasan, Thierry Berghmans, Anne‐Marie C. Dingemans	18
3	1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO) 2020 ·Annals of Oncology ·Marie Wislez, Julien Mazières, A. Lavolé, Gérard Zalcman, (unknown), Thomas Egenod, (unknown), R. Gervais, G. Jeannin, Olivier Molinier, Marie-Ange Massiani, Alexandra Langlais, Franck Morin, Françoise Le Pimpec‐Barthes, L. Brouchet, Jalal Assouad, B. Milleron, Diane Damotte, Martine Antoine, Virginie Westeel	40
4	Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation 2019 ·European Annals of Otorhinolaryngology Head and Neck Diseases ·(unknown), Idlir Licaj, B. Géry, R. Gervais, (unknown), E. Babin, D. De Raucourt, Alison Johnson, Juliette Thariat	6
5	OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial 2019 ·Journal of Thoracic Oncology ·Nathalie Baize, I. Monnet, Laurent Greillier, Margaux Geier, H. Léna, Henri Janicot, A. Vergnenègre, Jacky Créquit, R. Lamy, J.B. Auliac, J. Le Treut, H. Le Caer, R. Gervais, Éric Dansin, A. Madroszyk, (unknown), (unknown), Roland Schött, Patrick Saulnier, C. Chouaïd	5
6	Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence 2019 ·Supportive Care in Cancer ·Mélanie Dos Santos, Marie Lange, R. Gervais, Bénédicte Clarisse, (unknown), (unknown), Jean‐Michel Grellard, Natacha Heutte, Idlir Licaj, Florence Joly	15
7	Mésothéliomes malins et mutations constitutionnelles du gène BAP1 2019 ·Revue des Maladies Respiratoires ·(unknown), Pascaline Berthet, (unknown), Catherine Dubos‐Arvis, (unknown), R. Gervais	1
8	Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO 2018 ·Revue des Maladies Respiratoires ·(unknown), Martine Antoine, Denis Moro‐Sibilot, C. Dayen, B. Mennecier, R. Gervais, Elodie Amour, B. Milleron, Franck Morin, Gérard Zalcman, Marie Wislez	11
9	OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial. 2018 ·Journal of Thoracic Oncology ·Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol, Josiane Otto, Julien Mazières, Pierre Jean Souquet, Rastilav Bahleda, Marie Wislez, Sophie de Guibert, B. Mennecier, C. Chouaïd, Renaud Sabatier, Suzanna Bota, R. Gervais, Véronique Verrièle, Véronique Haddad, G. Ferretti, (unknown), Céline Mahier - Aït Oukhatar, Gilles Vassal	11
10	OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial. 2018 ·Journal of Thoracic Oncology ·Julien Mazières, (unknown), Fabrice Barlési, Bruno Coudert, Pierre Jean Souquet, Josiane Otto, R. Gervais, Denis Moro‐Sibilot, I. Monnet, Étienne Brain, Olivier Huillard, Gilles Quéré, D. Debieuvre, Elizabeth Fabre, M. Jaffro, S. Collot, G. Ferretti, Céline Tiffon, Céline Mahier - Aït Oukhatar, Jean‐Yves Blay	7
11	Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15 2017 ·Annals of Oncology ·R. Corre, R. Gervais, (unknown), Florian Guisier, R. Lamy, (unknown), Laurent Greillier, H. Doubre, C. Chouaïd, J.B. Auliac	1
12	LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy 2015 ·Annals of Oncology ·Roy S. Herbst, D.-W. Kim, Enriqueta Felip, José Luis Perez‐Gracia, (unknown), Ji‐Youn Han, Julian R. Molina, (unknown), R. Gervais, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, E. Im, Paul Baas	1
13	Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study 2015 ·Targeted Oncology ·J.B. Auliac, Charles Fournier, Clarisse Audigier-Valette, M. Pérol, (unknown), F. Viñas, (unknown), (unknown), R. Corre, G. Le Garff, P. Fournel, Nathalie Baize, R. Lamy, A. Vergnenègre, D. Arpin, Benôıt Marin, C. Chouaïd, R. Gervais	15
14	Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial 2014 ·Annals of Oncology ·Fabrice Barlési, Arnaud Scherpereel, В. А. Горбунова, R. Gervais, Anders Vikström, C. Chouaïd, Antonio Chella, (unknown), Myung‐Ju Ahn, Martin Reck, Antonio Pazzola, (unknown), Joachim G.J.V. Aerts, (unknown), Anderson Loundou, Harry J.M. Groen, Achim Rittmeyer	129
15	Measuring downsizing in organisations 2014 ·R. Gervais	1
16	Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) 2011 ·Annals of Oncology ·Fabrice Barlési, R. Gervais, H. Léna, J. Hureaux, H. Bérard, D. Paillotin, S. Bota, I. Monnet, Abdesslam Chajara, G. Robinet	181
17	Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc) 2010 ·Annals of Oncology ·Paul Lorigan, J.C. Soria, Joan Stephenson, (unknown), R. Gervais, (unknown), Ian McCaffery, (unknown), Jesse McGreivy, Bonnie S. Glisson	6
18	Global Outsourcing Strategies: An International Reference on Effective Outsourcing Relationships 2006 ·Medical Entomology and Zoology ·(unknown), R. Gervais	18
19	Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin 2005 ·Annals of Oncology ·Jean-Louis Pujol, Jean-Luc Breton, R. Gervais, Paul Rebattu, A Depierre, Jean‐François Morère, B. Milleron, D. Debieuvre, (unknown), P.-J. Souquet, Denis Moro‐Sibilot, É. Lemarié, Romain Kessler, Henri Janicot, David Braun, D. Spaëth, Xavier Quantin, C. Clary	101
20	Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) 2004 ·Annals of Oncology ·R. Gervais, A Ducoloné, Jean-Luc Breton, Denis Braun, B Lebeau, F. Vaylet, D. Debieuvre, Jean Louis Pujol, Jean Trédaniel, P. Clouet, Élisabeth Quoix	104

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact